Harmony Biosciences Holdings (HRMY) Return on Capital Employed (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Return on Capital Employed data on file, last reported at 17.97% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 491.0% year-over-year to 17.97%; the trailing twelve-month figure through Mar 2026 stood at 17.97% (down 491.0% YoY), and the FY2025 full-year result was 23.6%, down 253.0% from the prior year.
• Return on Capital Employed retreated to 17.97% in Q1 2026, from 21.1% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 30.44% in Q4 2023 to a low of 17.97% in Q1 2026.
• A 5-year average of 24.36% and a median of 24.14% in 2025 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed surged 1417 bps in 2022 and slumped 729 bps in 2025, its largest moves.
• Tracing HRMY's Return on Capital Employed over 5 years: stood at 20.73% in 2022, then jumped by 47 bps to 30.44% in 2023, then declined by 21 bps to 24.2% in 2024, then slipped by 13 bps to 21.1% in 2025, then slipped by 15 bps to 17.97% in 2026.
• Business Quant data shows HRMY's Return on Capital Employed at 17.97% in Q1 2026, 21.1% in Q4 2025, and 24.14% in Q3 2025.